Turkey
Massive Bio, founded in 2014, is revolutionizing the oncology sector with its AI-driven system that connects cancer patients to clinical trials in real-time, thereby industrializing the oncology action layer. Operating in 17 countries across North America, Europe, and LATAM, this Turkey-headquartered company is at the forefront of ensuring equitable trial access using proprietary AI technology.
With an extensive network, Massive Bio has onboarded over 200K patients and developed partnerships with 60+ pharmaceutical and CRO customers, as well as 130+ strategic partners. Its collaboration with the White House’s Cancer Moonshot underscores its industry influence.
The company’s latest $16.50M Series B funding on 01 December 2022 involved investors including Revo Capital, ImpactAssets, and Toyota Financial Services. With its focus on reducing dropout rates and delivering real-world evidence, Massive Bio represents a compelling investment opportunity in the intersection of AI and biotechnology.
